Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
4.920
+0.070 (1.44%)
Nov 22, 2024, 4:00 PM EST - Market closed

Company Description

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States.

The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014.

Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

Tenax Therapeutics, Inc.
Tenax Therapeutics logo
Country United States
Founded 1967
Industry Biotechnology
Sector Healthcare
Employees 6
CEO Christopher Giordano

Contact Details

Address:
101 Glen Lennox Drive, Suite 300
Chapel Hill, North Carolina 27517
United States
Phone (919) 855-2100
Website tenaxthera.com

Stock Details

Ticker Symbol TENX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000034956
CUSIP Number 88032L209
ISIN Number US88032L6056
Employer ID 26-2593535
SIC Code 2834

Key Executives

Name Position
Christopher T. Giordano Chief Executive Officer, President and Director
Dr. Stuart Rich M.D. Chief Medical Officer and Director
Lawrence R. Hoffman CPA, Esq. Interim Chief Financial Officer
Doug Randall Executive Vice President of Commercial and Business Operations
Dr. Douglas Hay Senior Vice President of Regulatory Affairs

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Nov 12, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Oct 30, 2024 8-K Current Report
Sep 27, 2024 DEF 14A Other definitive proxy statements
Sep 12, 2024 EFFECT Notice of Effectiveness